Table 3

Multivariate analyses of PFS and OS from the time of initiation of ICB-based therapy

Variable (reference)Progression-free survivalOverall survival
HR (95% CI)P valueHR (95% CI)P value
White race (nonwhite)0.179 (0.049 to 0.663)0.0100.127 (0.0277 to 0.586)0.008
Metastasis at diagnosis (no metastasis)0.399 (0.129 to 1.227)0.1090.628 (0.222 to 1.773)0.380
ICB monotherapy (ICB plus other)2.153 (0.613 to 7.557)0.2318.146 (1.680 to 39.510)0.009
Ipilimumab plus nivolumab (ICB plus other)5.326 (1.77 to 16.045)0.00311.598 (3.016 to 44.598)<0.001
CHN (soft tissue or visceral)0.164 (0.042 to 0.638)0.0090.197 (0.057 to 0.685)0.011
Non-CHN (soft tissue or visceral)0.284 (0.066 to 1.221)0.0910.546 (0.115 to 2.579)0.445
  • P values in bold are statistically significant per the pre-specified threshold of P < 0.05.

  • CHN, cutaneous angiosarcoma of the head and neck; ICB, immune checkpoint blockade; OS, overall survival; PFS, progression-free survival.